Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 5/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5894995 | 0.88 | DDB1 (0.44) | DDB1CRBNUSP2SMN1; SMN2GPR119 | |
| SCHEMBL31646257 | 0.79 | DDB1 (0.40) | DDB1CRBNUSP2SMN1; SMN2GPR119 | |
| SCHEMBL5897211 | 0.78 | DDB1 (0.42) | DDB1CRBNUSP2SMN1; SMN2GPR119 | |
| SCHEMBL23145355 | 0.77 | USP2 (0.45) | DDB1CRBNUSP2SMN1; SMN2GPR119 | |
| SCHEMBL14316377 | 0.77 | USP2 (0.45) | DDB1CRBNUSP2SMN1; SMN2GPR119 | |
| SCHEMBL31081976 | 0.76 | DDB1 (0.41) | DDB1CRBNUSP2SMN1; SMN2GPR119 | |
| SCHEMBL31646142 | 0.75 | HPGD (0.40) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL31645388 | 0.74 | ROCK2 (0.39) | DDB1CRBNGPR119KDM4EMAPT | |
| SCHEMBL5895323 | 0.74 | USP2 (0.47) | DDB1CRBNUSP2SMN1; SMN2GPR119 | |
| SCHEMBL1344048 | 0.73 | USP2 (0.50) | DDB1CRBNUSP2SMN1; SMN2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091211-B2 | Cyclopentyl modulators of chemokine receptor activity | MERCK & CO., INC. (US) | 2006-08-15 | — | — | US | disclosed |
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | MERCK SHARP & DOHME CORP. | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070609-A1 | Cyclopentyl modulators of chemokine receptor activity | CCR5, CXCR1, ACKR3 | DDB1 1167/4885CRBN 4573/4885USP2 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.